TherapeuticsMD (TXMD) Q3 2024 earnings summary

Executive summary

• Transitioned to a pharmaceutical royalty company after divesting commercial operations in December 2022, no longer engaging in R&D or commercial activities.

• Main revenue sources are royalties from Mayne Pharma, Theramex, and Knight for licensed products in the U.S. and internationally.

• Workforce reduced to one full-time executive, with external consultants supporting operations.

• Ongoing process to explore strategic alternatives, including acquisition, merger, asset sale, or other business combinations.

Financial highlights

• License revenue for Q3 2024 was $547K, up from $(53)K in Q3 2023 due to increased sales of licensed products.

• Net loss from continuing operations for Q3 2024 was $567K ($0.05/share), improved from $1.4M ($0.13/share) in Q3 2023.

• Operating expenses for Q3 2024 were $1.41M, down 18.3% year-over-year.

• Cash and cash equivalents as of September 30, 2024, totaled $5.05M.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to reliance on royalty income and potential need for additional capital.

• May pursue equity or debt financing; failure to secure funding may require curtailing operations or asset sales.

• Actively evaluating strategic alternatives, with no assurance on outcome or timing.